Dedicated to finding new medicines for a variety of diseases through the ubiquitin pathway, a critical mechanism of cellular regulation. Progenra's assay platform and unique profiling capacity can identify selective inhibitors of critical ubiquitin pathway enzymes associated with cancer, osteoporosis, and other debilitating diseases. This technology and multiple selective compounds are available for licensing.
Progenra’s goal is to discover novel drugs targeting the ubiquitin pathway using their proprietary technology.
E3 LIGASE TECHNOLOGY
Researchers at Progenra, Inc. announce the advanced online publication of the article “Selective Dual Inhibitors of the Cancer-related Deubiquitylating Proteases USP7 and USP47” (Weinstock, J. et al, ACS Medicinal Chemistry Letters). The new article presents evidence of a therapeutic benefit resulting from dual inhibition of USP7 and a related enzyme, USP47.
Progenra wishes to partner with industry and academic entities to further promote the distribution and use of its UbiPro™ Drug Discovery Platform and influence ubiquitin drug discovery on a global scale.